PRPH (ProPhase Labs) Net Margin %: -943.62% (As of Dec. 2025)


What is ProPhase Labs Net Margin %?

ProPhase Labs PRPH -4.61% Net Margin % is -943.62% as of Dec. 2025. The stock has 4 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, ProPhase Labs ranks worse than 87.75% on this metric.

Net margin is calculated as Net Income divided by its Revenue. ProPhase Labs's Net Income for the three months ended in Dec. 2025 was $-7.40 Mil. ProPhase Labs's Revenue for the three months ended in Dec. 2025 was $0.78 Mil. Therefore, ProPhase Labs's net margin for the quarter that ended in Dec. 2025 was -943.62%.

The historical rank and industry rank for ProPhase Labs's Net Margin % or its related term are showing as below:

PRPH' s Net Margin % Range Over the Past 10 Years
Min: -788.24   Med: -23.25   Max: 411.36
Current: -339.31

PRPH's Net Margin % is ranked worse than
87.75% of 204 companies
in the Medical Diagnostics & Research industry
Industry Median: -2.405 vs PRPH: -339.31

ProPhase Labs  (OTCPK:PRPH) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

ProPhase Labs Net Margin % Related Terms

ProPhase Labs Net Margin % Historical Data

* Premium members only.

The historical data trend for ProPhase Labs's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ProPhase Labs Net Margin % Chart

ProPhase Labs Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.94 15.05 -47.97 -788.24 -339.31

ProPhase Labs Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,299.80 277.15 -358.62 -774.52 -943.62

PRPH vs NSTM, IDTA, IVRO: Net Margin % Comparison

For the Diagnostics & Research subindustry, ProPhase Labs's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ProPhase Labs Net Margin % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, ProPhase Labs's Net Margin % distribution charts can be found below:

* The bar in red indicates where ProPhase Labs's Net Margin % falls into.


ProPhase Labs Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

ProPhase Labs's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-14.743/4.345
=-339.31 %

ProPhase Labs's Net Margin for the quarter that ended in Dec. 2025 is calculated as

Net Margin=Net Income (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-7.398/0.784
=-943.62 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of -943.62% mean?
ProPhase Labs (PRPH) has a Net Margin % of -943.62% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on ProPhase Labs and its competitors. According to the industry distribution chart, ProPhase Labs ranks #179 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 87.7%.
Is ProPhase Labs' Net Margin % too high?
ProPhase Labs' current Net Margin % is -943.62%. Based on the distribution chart, ProPhase Labs ranks #179 out of 204 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does ProPhase Labs' Net Margin % compare to NSTM and IDTA?
According to the Medical Diagnostics & Research industry distribution chart, ProPhase Labs ranks #179 out of 204 companies for Net Margin %. This places ProPhase Labs in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Diagnostics & Research company?
A good Net Margin % depends on the Medical Diagnostics & Research industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on ProPhase Labs and its competitors. ProPhase Labs's current Net Margin % is -943.62%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProPhase Labs stock overvalued right now?
Based on GuruFocus' analysis, ProPhase Labs (PRPH) is currently considered Possible Value Trap. The stock's GF Value™ is $0.65, compared to a current price of $0.09 — trading 86% below its estimated fair value. The current Net Margin % is -943.62%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For ProPhase Labs (PRPH), the current Net Margin % is -943.62% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ProPhase Labs Business Description

Address 626 RXR Plaza, 6th Floor, Uniondale, NY, USA, 11556
ProPhase Labs Inc oriented and diversified next generation biotech, genomics and consumer products company that develops and commercializes novel drugs, dietary supplements, and compounds, and human genomic testing. It offer whole genome sequencing and related services. It maintain two operating segments: diagnostic services (which includes its COVID-19 and other diagnostic testing services) and consumer products. It generates majority of revenue from consumer products segment which engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services.